| Literature DB >> 34270366 |
Alhassane Diallo1, Miguel Carlos-Bolumbu2, Minerva Cervantes-Gonzalez3, Veronika Wozniak4, Mamadou Hassimiou Diallo5, Boubacar Djelo Diallo6, Alexandre Delamou7, Florence Galtier8.
Abstract
Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety. A total of 21 randomized controlled trial, evaluating seven different vaccines with different doses, and 5,275 participants were analyzed. The rVSVΔG-ZEBOV-GP (2 × 10 7) vaccine was more immunogenic (P-score 0.80). For pain, rVSVΔG-ZEBOV-GP (≤10 5) had few events (P-score 0.90). For fatigue and headache, the DNA-EBOV (≤ 4 mg) was the best one with P-scores of 0.94 and 0.87, respectively. For myalgia, the ChAd3 (10 10) had a lower risk (P-score 0.94). For fever, the Ad5.ZEBOV (≤ 8 × 10 10) was the best one (P-score 0.80). The best vaccine to be used to stop future outbreak of Ebola is the rVSVDG-ZEBOV-GP vaccine at dose of 2 × 107 PFU.Entities:
Keywords: Ebolavirus; healthy volunteer; network meta-analysis; vaccine
Mesh：
Substances：
Year: 2021 PMID： 34270366 PMCID： PMC8437548 DOI： 10.1080/21645515.2021.1932214
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 4.526